American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer

Brachytherapy

Volumn 10, Issue 5, 2011, Pages 357-362

  Frank, Steven J ^a   Arterbery, V Elayne ^b   Hsu, I Chow Joe ^c   Abdel Wahab, May ^d   Ciezki, Jay P ^e   Hahn, Noah M ^f   Mohler, James Lloyd ^g   Moran, Brian J ^h   Rosenthal, Seth A ⁱ   Rossi, Carl J ^j   Yamada, Yoshiya ^k   Merrick, Gregory ^l  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Crittenton DMC Health Service   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h Chicago Prostate Cancer Center   (United States)

ⁱ Radiological Associates of Sacramento Medical Group Inc   (United States)

^j LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l WHEELING HOSPITAL   (United States)

more..

Author keywords

Appropriateness criteria; Brachytherapy; Prostate cancer; Quality of life; Radiation therapy; Standard of care

Indexed keywords

CESIUM 131; IODINE 125; PALLADIUM 103;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CONSENSUS; DELPHI STUDY; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; MORBIDITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TREATMENT PLANNING; VIGNETTE;

ANDROGEN ANTAGONISTS; BRACHYTHERAPY; HUMANS; MALE; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTHESES AND IMPLANTS; QUALITY OF LIFE; RADIOISOTOPES;

EID: 80052309267     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.01.014     Document Type: Article

References (50)

1. National Comprehensive Cancer Network. Available at: Accessed March 31, 2010. http://www.nccn.com/prostate_cancer.aspx.
2. Frank S.J., Pisters L.L., Davis J., et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007, 177:2151-2156. discussion 2156.
3. Merrick G.S., Wallner K.E., Butler W.M. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 2003, 169:1643-1652.
4. Stock R.G., Cesaretti J.A., Stone N.N. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 2006, 64:810-816.
5. Sylvester J.E., Blasko J.C., Grimm P.D., et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003, 57:944-952.
6. D'Souza W.D., Thames H.D., Kuban D.A. Dose-volume conundrum for response of prostate cancer to brachytherapy: Summary dosimetric measures and their relationship to tumor control probability. Int J Radiat Oncol Biol Phys 2004, 58:1540-1548.
7. American College of Radiology: ACR Practice Guideline for the ACR-ASTRO practice guideling for transperineal permanent brachtytherapy of prostate cancer. Available at: Accessed October 1, 2010. http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/brachy_prostate_cancer.aspx.
8. Ash D., Flynn A., Battermann J., et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000, 57:315-321.
9. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002, 12:81-94.
10. Crook J., Lukka H., Klotz L., et al. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 2001, 164:975-981.
11. Bellon J., Wallner K., Ellis W., et al. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 43:579-581.
12. Wallner K., Smathers S., Sutlief S., et al. Prostate brachytherapy in patients with median lobe hyperplasia. Int J Cancer 2000, 90:152-156.
13. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 53:91-98.
14. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998, 160:1379-1382.
15. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003, 56:454-461.
16. Merrick G.S., Butler W.M., Wallner K.E., et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002, 60:650-655.
17. Stone N.N., Ratnow E.R., Stock R.G. Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol 2000, 6:123-127.
18. Wallner K., Lee H., Wasserman S., et al. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997, 37:565-569.
19. Merrick G.S., Butler W.M., Wallner K.E., et al. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004, 58:81-88.
20. Merrick G.S., Wallner K.E., Butler W.M. Patient selection for prostate brachytherapy: More myth than fact. Oncology (Williston Park) 2004, 18:445-452. [discussion 452, 455-447].
21. Bradley R.P., William S.B. Clinical outcomes of a Phase II, multi-institutional Cesium-131 permanent prostate brachytherapy trial. Brachytherapy 2007, 6:78.
22. Radiation Therapy Oncology Group. RTOG 0232. A Phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic carcinoma. Available at: Accessed March 31, 2010. http://www.rtog.org/members/protocols/0232/0232.pdf.
23. Butler W.M., Merrick G.S., Lief J.H., et al. Comparison of seed loading approaches in prostate brachytherapy. Med Phys 2000, 27:381-392.
24. Cohen G.N., Amols H.I., Zelefsky M.J., et al. The Anderson nomograms for permanent interstitial prostate implants: A briefing for practitioners. Int J Radiat Oncol Biol Phys 2002, 53:504-511.
25. Kudchadker R.J., Swanson D.A., Kuban D.A., et al. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?. Int J Radiat Oncol Biol Phys 2008, 72:623-627.
26. Nath R., Bice W.S., Butler W.M., et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Med Phys 2009, 36:5310-5322.
27. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998, 41:101-108.
28. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 2005, 62:981-987.
29. Han B.H., Wallner K.E. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications. Int J Cancer 2001, 96:372-378.
30. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001, 50:335-341.
31. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000, 46:839-850.
32. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001, 51:31-40.
33. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005, 173:1562-1566.
34. Blasko J.C., Grimm P.D., Sylsvester J.E., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000, 57:273-278.
35. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:32-43.
36. Lee L.N., Stock R.G., Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002, 52:444-452.
37. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 2000, 48:111-117.
38. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
39. Kwok Y., DiBiase S.J., Amin P.P., et al. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002, 53:588-594.
40. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 1999, 85:2630-2637.
41. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 2000, 55:382-386.
42. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer 2003, 97:979-983.
43. Merrick G.S. The role of hormonal therapy in prostate brachytherapy. Counterpoint. Brachytherapy 2003, 2:2-4.
44. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000, 18:1187-1192.
45. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911.
46. Stock R.G., Cesaretti J.A., Stone N.N. Comparisons of PSA failure definitions following trimodality therapy for intermediate to high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2007, 69:S344-S345.
47. Caloglu M., Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: Review of a confusing phenomenon. Urology 2009, 74:1183-1190.
48. Merrick G.S., Butler W.M., Wallner K.E., et al. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 54:450-456.
49. Reed D., Wallner K., Merrick G., et al. Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. Urology 2003, 62:683-688.
50. Crook J., Gillian C., Yeung I., et al. PSA kinetics and PSA bounce following permanent seed prostate bracytherapy. Int J Radiat Oncol Biol Phys 2007, 69:426-433.